Once ignored by drug-development companies, a treatment for a disfiguring skin cancer could hit the market as soon as next year.
Genentech Inc., which has been working with Curis Inc. (NASDAQ: CRIS) of Cambridge, Mass., has submitted a new drug application to the Food and Drug Administration for its drug, vismodegib. It is aimed at patients with advanced basal cell carcinoma for whom surgery is considered inappropriate.
No comments:
Post a Comment